Efficacy and harms of long‐term opioid therapy in chronic non‐cancer pain: Systematic review and meta‐analysis of open‐label extension trials with a study duration ≥26 weeks

This updated systematic review evaluated the efficacy, acceptability and safety of long‐term opioid therapy (LTOT) for chronic non‐cancer pain (CNCP).

[1]  N. Seitz,et al.  Trends In Substance Use And Related Disorders. , 2019, Deutsches Arzteblatt international.

[2]  Hyon K. Choi,et al.  Association of Tramadol With All-Cause Mortality Among Patients With Osteoarthritis , 2019, JAMA.

[3]  N. Seitz,et al.  Estimation of the Number of People With Opioid Addiction in Germany. , 2019, Deutsches Arzteblatt international.

[4]  N. Volkow,et al.  Prevention and Treatment of Opioid Misuse and Addiction: A Review , 2019, JAMA psychiatry.

[5]  M. Kawamata,et al.  Efficacy and safety of controlled-release oxycodone for the management of moderate-to-severe chronic low back pain in Japan: results of an enriched enrollment randomized withdrawal study followed by an open-label extension study , 2019, Journal of pain research.

[6]  H. Sadeghi-Nejad,et al.  Management Strategies in Opioid Abuse and Sexual Dysfunction: A Review of Opioid-Induced Androgen Deficiency. , 2018, Sexual medicine reviews.

[7]  A. Eschalier,et al.  Prescription opioid analgesic use in France: Trends and impact on morbidity–mortality , 2018, European journal of pain.

[8]  Hongyi Xu,et al.  Social commerce: A systematic review and data synthesis , 2018, Electron. Commer. Res. Appl..

[9]  S. Marshall,et al.  Methodologic limitations of prescription opioid safety research and recommendations for improving the evidence base , 2018, Pharmacoepidemiology and drug safety.

[10]  Nabarun Dasgupta,et al.  Opioid Crisis: No Easy Fix to Its Social and Economic Determinants. , 2018, American journal of public health.

[11]  Mark Edmund Rose,et al.  Are Prescription Opioids Driving the Opioid Crisis? Assumptions vs Facts , 2017, Pain medicine.

[12]  F. Chung,et al.  Opioids, respiratory depression, and sleep-disordered breathing. , 2017, Best practice & research. Clinical anaesthesiology.

[13]  Joseph W. Frank,et al.  Guideline for opioid therapy and chronic noncancer pain , 2017, Canadian Medical Association Journal.

[14]  A. Furlan,et al.  The opioid epidemic and national guidelines for opioid therapy for chronic noncancer pain: a perspective from different continents , 2017, Pain reports.

[15]  R. Deyo,et al.  Comparison of Opioid Prescribing Patterns in the United States and Japan: Primary Care Physicians' Attitudes and Perceptions , 2017, The Journal of the American Board of Family Medicine.

[16]  K. Slavin,et al.  Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines. , 2017, Pain physician.

[17]  R. Rauck,et al.  Long-term safety and analgesic efficacy of buprenorphine buccal film in patients with moderate-to-severe chronic pain requiring around-the-clock opioids , 2017, Journal of pain research.

[18]  J. Pérez-Cajaraville,et al.  European Pain Federation position paper on appropriate opioid use in chronic pain management , 2016, European journal of pain.

[19]  K. Murray,et al.  Prescription of Long-Acting Opioids and Mortality in Patients With Chronic Noncancer Pain. , 2016, JAMA.

[20]  R. Chou,et al.  CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. , 2016, JAMA.

[21]  P. Vergne-Salle,et al.  [Use of strong opioids in chronic non-cancer pain in adults. Evidence-based recommendations from the French Society for the Study and Treatment of Pain]. , 2016, Presse medicale.

[22]  R. Chou,et al.  CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. , 2016, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[23]  Stephen A. Rappaport,et al.  Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial. , 2015, Clinical therapeutics.

[24]  Yuju Ma,et al.  Twelve-month, open-label assessment of long-term safety and abuse potential of hydrocodone extended-release formulated with abuse-deterrence technology in patients with chronic pain. , 2015, Journal of opioid management.

[25]  C. Maier,et al.  Erratum zu: Langzeittherapie mit Opioiden bei chronischem nicht-tumorbedingtem Schmerz , 2015, Der Schmerz.

[26]  K. Vowles,et al.  Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis , 2015, Pain.

[27]  R. Chou,et al.  The Effectiveness and Risks of Long-Term Opioid Therapy for Chronic Pain: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop , 2015, Annals of Internal Medicine.

[28]  L. Radbruch,et al.  [Recommendations of the updated LONTS guidelines. Long-term opioid therapy for chronic noncancer pain]. , 2015, Schmerz.

[29]  C. Sommer,et al.  Opioide bei chronischem Kreuzschmerz , 2015, Der Schmerz.

[30]  F. Petzke,et al.  Opioide bei chronischem Arthroseschmerz , 2015, Der Schmerz.

[31]  F. Petzke,et al.  Opioide bei chronischem neuropathischem Schmerz , 2014, Der Schmerz.

[32]  M. Hopp,et al.  Long-term evaluation of combined prolonged-release oxycodone and naloxone in patients with moderate-to-severe chronic pain: pooled analysis of extension phases of two Phase III trials , 2014, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[33]  R. Dworkin,et al.  Abuse liability measures for use in analgesic clinical trials in patients with pain: IMMPACT recommendations , 2013, PAIN®.

[34]  G. Guyatt,et al.  Assessing and presenting summaries of evidence in Cochrane Reviews , 2013, Systematic Reviews.

[35]  I. Sutton,et al.  Controlled-release oxycodone and naloxone in the treatment of chronic low back pain: a placebo-controlled, randomized study. , 2013, Pain research & management.

[36]  R. Sabatowski,et al.  Sustained Safety and Efficacy of Once‐Daily Hydromorphone Extended‐Release (OROS® hydromorphone ER) Compared with Twice‐Daily Oxycodone Controlled‐Release Over 52 Weeks in Patients with Moderate to Severe Chronic Noncancer Pain , 2013, Pain practice : the official journal of World Institute of Pain.

[37]  J. Ballantyne,et al.  Opioid Dependence vs Addiction: A Distinction Without a Difference? , 2012, Archives of internal medicine.

[38]  Joseph A Boscarino,et al.  Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system. , 2010, Addiction.

[39]  C. Eccleston,et al.  “Evidence” in chronic pain – establishing best practice in the reporting of systematic reviews , 2010, PAIN.

[40]  A. Sandner-Kiesling,et al.  Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain , 2010, International journal of clinical practice.

[41]  S. Rashiq,et al.  Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. , 2010, Clinical therapeutics.

[42]  S. Tregear,et al.  Long-term opioid management for chronic noncancer pain. , 2010, The Cochrane database of systematic reviews.

[43]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[44]  C. Rutter,et al.  De Facto Long-term Opioid Therapy for Noncancer Pain , 2008, The Clinical journal of pain.

[45]  C. Thorne,et al.  A randomized, double-blind, crossover comparison of the efficacy and safety of oral controlled-release tramadol and placebo in patients with painful osteoarthritis. , 2008, Pain research & management.

[46]  J. Farrar,et al.  Long-term Use of Controlled-release Oxycodone for Noncancer Pain: Results of a 3-year Registry Study , 2007, The Clinical journal of pain.

[47]  M. Zenz,et al.  [Long-term efficiency of opioid medication in patients with chronic non-cancer-associated pain. Results of a survey 5 years after onset of medical treatment]. , 2005, Schmerz.

[48]  H. Ahdieh,et al.  Safety, Tolerability, and Effectiveness of Oxymorphone Extended Release for Moderate to Severe Osteoarthritis Pain: A One-Year Study , 2005, American journal of therapeutics.

[49]  J. Hildebrandt,et al.  Morphine responsiveness, efficacy and tolerability in patients with chronic non-tumor associated pain – results of a double-blind placebo-controlled trial (MONTAS) , 2002, Pain.

[50]  J. Caldwell,et al.  Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. , 2002, Journal of pain and symptom management.

[51]  R. Fleischmann,et al.  Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. , 2000, Archives of internal medicine.

[52]  P. Raskin,et al.  Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. , 2000, Journal of diabetes and its complications.

[53]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[54]  C. Begg,et al.  Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.

[55]  Robert G. Orwin,et al.  A Fail-SafeN for Effect Size in Meta-Analysis , 1983 .

[56]  R. Orwin.  A fail-safe N for effect size in meta-analysis. , 1983 .

[57]  J. O'sullivan,et al.  Cushing's syndrome: clinical differential diagnosis and complications. , 1959, Annals of internal medicine.

[58]  Innere Medizin.  Long-term opioid therapy in chronic noncancer pain A systematic review and meta-analysis of efficacy, tolerability and safety in open-label extension trials with study duration of at least 26 weeks , 2015 .

[59]  C. Maier,et al.  [Long-term opioid therapy in chronic noncancer pain. A systematic review and meta-analysis of efficacy, tolerability and safety in open-label extension trials with study duration of at least 26 weeks]. , 2015, Schmerz.

[60]  Comprehensive Meta‐Analysis Software , 2022, Introduction to Meta‐Analysis.